Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo – – An Exploratory Analysis of CLEAR ...

Medifast, the health and wellness company known for its science-backed, coach-guided lifestyle system, continues to lead the charge in addressing the growing health crisis of metabolic dysfunction by ...

MolecuLight will be exhibiting at the 2025 International Post-Acute Wound Care Society (IPAWS) Summit, where the company will showcase this significant publication alongside multiple scientific ...

Company to also present at the Advanced Recycling Conference (Germany) and the 2nd Annual Sustainable Flexible Packaging ...

Among obstetric providers, 42.3% reported only making one allergy/immunology referral in pregnancy per year, according to ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at ...

Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and ...

IMUNON Presents Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting – On November 7, 2025, the Company presented translational data from the Phase 2 OVATION 2 ...

Khalifa University of Science and Technology has reaffirmed its role as a catalyst for research and knowledge exchange by hosting the 3rd Healthy Longevity Symposium featuring the Nature Forum: ...

Atea Pharmaceuticals, Inc. ( AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements November 13, 2025 10:00 AM EST Jordan Feld Anthony Martinez Nancy Reau Eric ...

MRT-8102 is a selective, potent, and durable NEK7 degrader. Activation of the NLRP3 inflammasome critically depends on NEK7. Administration of MRT-8102 led to inhibition of NLRP3 inflammasome in vitro ...

Good morning, ladies and gentlemen, and welcome to the Cellectar Biosciences' Third Quarter 2025 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 13, 2025. I ...